Dr. Erba's research focus is on clinical development of novel therapies for acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms (such as chronic myeloid leukemia, polycythemia vera, essential thrombocythemia and myelofibrosis), and acute lymphoblastic leukemia. Specifically, he has been the Principal Investigator for small molecular inhibitors, antibody-drug conjugates and cytotoxic chemotherapy. Dr. Erba has been an active member of teams of doctors that have brought new treatments to people with AML, such as oral drugs that inactivate FLT3 and IDH.

Get the latest thought leadership on AML delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.

Thanks to our HealthTree Community for AML Sponsors:

Bristol Myers Squibb
Jazz Pharmaceuticals
AbbVie
Genentech
Amgen

Follow Us

facebook instagram twitter youtube

 

Terms of Use and Privacy Policy     Newsroom     About    Donations    Find an AML Specialist     Newsletter     Learn     Connect

 

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

https://www.guidestar.org/profile/45-5354811